- Ardelyx (ARDX, Financial) to present three studies at Digestive Disease Week 2025 Conference in San Diego.
- Focus on IBSRELA® (tenapanor) research in pediatric safety, breast milk pharmacokinetics, and financial burden of IBS-C.
- Sponsored Product Theater to discuss IBSRELA's mechanism and clinical application for IBS-C treatment.
Ardelyx, Inc. (ARDX), a biopharmaceutical company, announced the acceptance of three abstracts for poster presentations at the upcoming Digestive Disease Week Conference (DDW), scheduled in San Diego from May 3-6, 2025. These presentations will focus on IBSRELA® (tenapanor), an FDA-approved medication for treating irritable bowel syndrome with constipation (IBS-C) in adults. The company will highlight research involving the safety of tenapanor in pediatric patients, its pharmacokinetics in breast milk, and the correlation between IBS-C symptom severity and financial burden in patients.
The first poster presentation titled "Safety and Tolerability of Tenapanor in Pediatric Patients With Irritable Bowel Syndrome With Constipation" discusses data from a Phase 3 study and open-label extension. The second, "Neither Tenapanor nor its Major Metabolite Were Detected in the Breast Milk of Healthy Lactating Females," is based on a Phase 1 pharmacokinetic study. The third poster, "Patient-Reported IBS-C Symptom Severity Correlates Positively With Financial Burden," highlights results from the IBS in America 2024 survey. Ardelyx will also sponsor a Product Theater on May 4, featuring Dr. Satish Rao and Christina Hanson, NP, who will discuss IBSRELA’s mechanism of action and its integration into IBS-C treatment regimes, supported by interactive patient case studies and data from Phase 3 clinical trials.
IBSRELA is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which plays a significant role in reducing sodium absorption in the intestine and thereby helping in maintaining luminal water content, improving stool consistency, and reducing abdominal pain through its effects on intestinal permeability and visceral hypersensitivity.
Ardelyx continues to advance its research endeavors by exploring new patient populations and analyzing the economic impacts of IBS-C, showcasing their commitment to enhancing treatment options and understanding the broader implications of IBS-C on patients' lives.
